Zobrazit v EDS

Fc-effector functional antibody assays for SARS-CoV-2 variants of concern.

Uloženo v:
Podrobná bibliografie
Název: Fc-effector functional antibody assays for SARS-CoV-2 variants of concern.
Autoři: Chen, Xuemin, Li, Grace, Ciric, Caroline, Gibson, Theda, Anderson, Larry J., Rostad, Christina A.
Zdroj: Frontiers in Immunology; 2025, p1-13, 13p
Témata: ANTIBODY-dependent cell cytotoxicity, SARS-CoV-2, BOOSTER vaccines, SARS-CoV-2 Omicron variant, IMMUNE response
Abstrakt: Background: The Fc regions of antibodies mediate important effector cell functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and complement-dependent cytotoxicity (CDC). These functions enhance immune defense and infected cell clearance. This study evaluated the effect COVID-19 XBB.1.5 booster vaccination on Fc-effector antibody responses to SARS-CoV-2. Methods: We developed four assays to evaluate the Fc-effector functions of SARS-CoV-2 antibodies. ADCC and CDC assays utilized stably transfected luciferase-based target cell lines expressing SARS-CoV-2 spike variants (Ancestral, Wu-1 Omicron XBB.1.5, and EG.5) to measure antibody-mediated lysis by effector cells. ADCP and ADNP were assessed by flow cytometry to measure phagocytosis of fluorescently labeled virus-like particles that display SARS-CoV-2 variant spike proteins. Serum samples from 20 healthy adult volunteers pre- and post-monovalent XBB.1.5 COVID-19 vaccine were analyzed for pseudovirus neutralizing and Fc-effector antibodies. Results: Prior to administration of the COVID-19 XBB.1.5 booster vaccination, cross-neutralizing antibodies against XBB.1.5 and EG.5 variants were minimally detectable, while cross-functional Fc-effector antibodies were present at higher baseline levels. The COVID-19 XBB.1.5 booster vaccination significantly boosted both neutralizing and Fc-effector antibodies in magnitude and breadth. The greatest increase in neutralizing antibodies was against the XBB.1.5 strain, while Fc-effector functional antibodies had similar fold-increases in antibody titers against the breadth of SARS-CoV-2 variants tested. Neutralizing and Fc-effector antibodies were most highly correlated at baseline (prior to booster vaccination) but were less correlated post-vaccination, consistent with differential boosting of neutralizing vs Fc-effector antibodies by the monovalent vaccine. Conclusion: The COVID-19 XBB.1.5 booster vaccination significantly improved the magnitude, breadth, and quality of antibody responses to SARS-CoV-2. Combining Fc-mediated functional and neutralizing antibody assays provides a more comprehensive model for understanding vaccine-induced immunity and optimizing vaccination strategies. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Immunology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Complementary Index
Popis
Abstrakt:Background: The Fc regions of antibodies mediate important effector cell functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and complement-dependent cytotoxicity (CDC). These functions enhance immune defense and infected cell clearance. This study evaluated the effect COVID-19 XBB.1.5 booster vaccination on Fc-effector antibody responses to SARS-CoV-2. Methods: We developed four assays to evaluate the Fc-effector functions of SARS-CoV-2 antibodies. ADCC and CDC assays utilized stably transfected luciferase-based target cell lines expressing SARS-CoV-2 spike variants (Ancestral, Wu-1 Omicron XBB.1.5, and EG.5) to measure antibody-mediated lysis by effector cells. ADCP and ADNP were assessed by flow cytometry to measure phagocytosis of fluorescently labeled virus-like particles that display SARS-CoV-2 variant spike proteins. Serum samples from 20 healthy adult volunteers pre- and post-monovalent XBB.1.5 COVID-19 vaccine were analyzed for pseudovirus neutralizing and Fc-effector antibodies. Results: Prior to administration of the COVID-19 XBB.1.5 booster vaccination, cross-neutralizing antibodies against XBB.1.5 and EG.5 variants were minimally detectable, while cross-functional Fc-effector antibodies were present at higher baseline levels. The COVID-19 XBB.1.5 booster vaccination significantly boosted both neutralizing and Fc-effector antibodies in magnitude and breadth. The greatest increase in neutralizing antibodies was against the XBB.1.5 strain, while Fc-effector functional antibodies had similar fold-increases in antibody titers against the breadth of SARS-CoV-2 variants tested. Neutralizing and Fc-effector antibodies were most highly correlated at baseline (prior to booster vaccination) but were less correlated post-vaccination, consistent with differential boosting of neutralizing vs Fc-effector antibodies by the monovalent vaccine. Conclusion: The COVID-19 XBB.1.5 booster vaccination significantly improved the magnitude, breadth, and quality of antibody responses to SARS-CoV-2. Combining Fc-mediated functional and neutralizing antibody assays provides a more comprehensive model for understanding vaccine-induced immunity and optimizing vaccination strategies. [ABSTRACT FROM AUTHOR]
ISSN:16643224
DOI:10.3389/fimmu.2025.1571835